Thus, we believe IDH1 may similarly modulate clinical responses in distinct immunotherapies, tumors, and perhaps even in distinct immune-affected disorders, although we examined DC vaccine therapy for glioma exclusively. The gene discussed is IDH1; the disease is central nervous system cancer.